DiaboFood: How Its Ingredients Support Diabetes Mellitus Management

Introduction

Diabetes has become one of the biggest health problems in the world today. According to the International Diabetes Federation (IDF), around 589 million adults were living with diabetes in 2024, and this number is expected to reach 853 million by 2050.1 India is one of the most affected countries in the world. In fact, it is often called the "Diabetes Capital of the World" because more than 101 million Indian adults have diabetes, and another 136 million have prediabetes - a condition where blood sugar levels are higher than normal but not yet at the diabetic range. Most of these people do not even know they have it.2

So why are so many people getting diabetes? There is no single answer. A combination of factors is responsible - gaining too much weight, not getting enough physical activity, eating too much junk and processed food, living under constant stress, moving to cities, and simply getting older. All of these things together make it much easier for the body to lose control of its blood sugar levels.3–5

One of the most important signs of this loss of control is high fasting blood sugar - that is, elevated blood sugar levels measured after not eating for several hours. When fasting blood sugar stays high over time, it means the body is struggling in several ways: the cells are not responding properly to insulin, the pancreas is working harder than it should, the liver is releasing too much sugar into the blood, harmful molecules called free radicals are building up, and silent inflammation is taking place inside the body.6–9 On top of all this, recent research has shown that the balance of bacteria in the gut also plays a role in how the body manages blood sugar.10

Because so many things go wrong at the same time, managing blood sugar effectively requires more than just one solution. It requires an approach that tackles several problems together - improving how the body uses insulin, reducing oxidative damage, reduce the inflammation, and supporting gut health all at once.

Ayurveda has used certain plants for centuries to help control blood sugar, and modern science is now beginning to confirm their benefits. Plants like Gymnema sylvestre  (Madhunashin), Salacia reticulata (Saptarangi), Pterocarpus marsupium (Vijayasar), Syzygium cumini (Jamun), and Momordica charantia (Karela) have all been studied for their ability to support healthy blood sugar levels.11 Curcuma longa (Turmeric) and Emblica officinalis (Amla) help protect the body from oxidative damage.12,13 Fructo Oligosaccharides (FOS) act as food for good gut bacteria and may help improve the way the gut and metabolism work together.14 Vitamin B12 supports the body's energy production and helps keep the nervous system healthy - both of which can be affected when blood sugar is poorly controlled.15

DiaboFood® is a carefully developed nutritional supplement that brings all of these natural ingredients together. It combines proven plant extracts, gut-friendly fiber, and Vitamin B12 to help maintain healthy fasting blood sugar levels, support better blood sugar balance, and promote overall metabolic health. This paper looks at the scientific evidence behind each ingredient in DiaboFood® and explains how they may work together to support healthy blood sugar and metabolism.

Clinical Evidence Supporting the Role of Gymnema sylvestre in Glycemic Control

A study involving 200 patients demonstrated that supplementation with 6 g/day of Gudmar leaf powder resulted in a significant reduction in FBS from 189.93 mg/dl to 157.77 mg/dl after three months, compared to a non-significant decrease in the placebo group. HbA1c levels also showed a significant decline from 8.65% to 7.70% in the Gudmar group, indicating improved long-term glycemic control.16

Gymnema sylvestre  has demonstrated significant antihyperglycemic activity in patients with type 2 diabetes mellitus. In an open-label clinical study involving 39 individuals with type 2 diabetes, supplementation with Gymnema sylvestre  leaf extract (500 mg/day) for 90 days resulted in a significant improvement in glycemic control. Fasting blood glucose levels decreased from 188.9 ± 63.7 mg/dL at baseline to 162.7 ± 37.8 mg/dL after supplementation (p < 0.005). Postprandial blood glucose levels were also significantly reduced from 275.3 ± 103.0 mg/dL  to 216.0 ± 72.3 mg/dL (p < 0.001). Furthermore, glycated hemoglobin (HbA1c), a marker of long-term glycemic control, declined significantly from 9.6 ± 1.9% to 8.6 ± 1.6% following treatment (p < 0.001). The study additionally reported improvements in insulin sensitivity, β-cell function, triglyceride levels, and microalbuminuria, suggesting broader metabolic benefits beyond glucose regulation. These findings indicate that Gymnema sylvestre  may serve as a valuable adjunct in the management of type 2 diabetes and associated metabolic disturbances.17

In a 12-week prospective, open-label clinical study involving 30 patients with inadequately controlled type 2 diabetes mellitus, supplementation with a formulation containing 500 mg/day of standardized Gymnema sylvestre  leaf extract (≥75% gymnemic acids), magnesium, and vitamin D3 produced significant improvements in glycemic parameters. HbA1c levels decreased from a median baseline value of 8.10% to 7.00% after 12 weeks, representing a median reduction of 1.20 percentage points (p < 0.001). Furthermore, fasting plasma glucose (FPG) declined significantly from 140.75 mg/dL to 120.13 mg/dL, corresponding to a median reduction of 20.29 mg/dL (p < 0.001). Postprandial plasma glucose (PPG) also decreased markedly from 210.42 mg/dL to 177.29 mg/dL, with a median reduction of 33.13 mg/dL (p < 0.001). Notably, 90% of participants achieved HbA1c levels below 7.5% by the end of the intervention. In addition to glycemic improvements, participants experienced a significant reduction in sugar cravings and improvements in quality-of-life parameters, while no serious adverse events were reported. These findings suggest that Gymnema sylvestre  may contribute to improved glucose homeostasis, reduced postprandial glycemic excursions, and enhanced metabolic well-being in individuals with type 2 diabetes mellitus.18

Clinical Efficacy

The clinical study of Gudmar (Gymnema sylvestre ) highlights its potential as an effective treatment for glycemic control in diabetes management. Research indicates that Gudmar possesses anti-diabetic properties, which can significantly lower fasting blood sugar (FBS) and glycosylated hemoglobin (HbA1c) levels in patients with type 2 diabetes mellitus.

Mechanisms of Gymnema sylvestre

The anti-diabetic effects of Gudmar are attributed to its active compounds, including saponins and glycosides, which enhance insulin sensitivity and reduce sugar absorption in the intestines.19

Additionally, the polyherbal formulation containing Gudmar has been shown to reduce cholesterol and triglyceride levels, further supporting cardiovascular health in pre-diabetic individuals.20

While Gudmar shows promise in managing diabetes, it is essential to consider that individual responses may vary, and further large-scale studies are necessary to confirm its efficacy and safety across diverse populations.

Clinical Evidence Supporting the Role of Syzygium cumini in Glycemic Control

The antidiabetic potential of Syzygium cumini (Jamun) seed powder has been evaluated in a double-blind randomized controlled trial involving 99 patients with poorly controlled type 2 diabetes mellitus. Participants in the intervention group received 10 g/day of Jamun seed powder (5 g twice daily before meals) along with their regular oral hypoglycemic therapy, while the control group received a placebo. The intervention was continued for 90 days. The study demonstrated that Jamun seed powder supplementation significantly improved glycemic control and lipid parameters compared with placebo. At baseline, the intervention group had a mean fasting plasma glucose (FPG) level of 143 ± 13.42 mg/dL, postprandial plasma glucose (PPG) level of 242 ± 29.06 mg/dL, and HbA1c level of 8.99 ± 1.39%. The investigators reported significant improvements in glycemic control following supplementation, along with favorable effects on dyslipidemia, suggesting that Jamun seed powder may serve as a valuable adjunctive dietary intervention in the management of type 2 diabetes mellitus. Furthermore, the intervention was well tolerated and may contribute to reducing the risk of long-term diabetic complications through improved metabolic control.21

A double-blind randomized controlled trial involving 99 patients with poorly controlled type 2 diabetes mellitus evaluated the effects of Syzygium cumini (Jamun) seed powder supplementation at a dose of 10 g/day for 90 days. The intervention significantly reduced fasting plasma glucose from 143 ± 13.42 mg/dL to 110 ± 15.49 mg/dL (30% reduction), postprandial plasma glucose from 242 ± 29.06 mg/dL to 199 ± 29.92 mg/dL (21.61% reduction), and HbA1c from 8.99 ± 1.39% to 8.31 ± 1.40%. These findings suggest that Jamun seed powder may effectively improve glycemic control and serve as a beneficial adjunct in the management of type 2 diabetes mellitus. In contrast, the placebo group showed slight increases in fasting glucose, postprandial glucose, and HbA1c during the study period. The observed antidiabetic effects are attributed to the rich phytochemical composition of Jamun seeds, including flavonoids, anthocyanins, glycosides, tannins, saponins, and triterpenoids. Experimental evidence suggests that these bioactive constituents may enhance pancreatic β-cell function, stimulate insulin secretion, improve insulin sensitivity, inhibit carbohydrate-digesting enzymes such as α-amylase and α-glucosidase, and regulate glucose metabolism.22

Clinical Significance of Syzygium cumini

Clinical evidence suggests that Syzygium cumini exhibits promising antidiabetic effects and may serve as a beneficial adjunct in diabetes management. Supplementation with Jamun seed powder has been shown to significantly reduce fasting plasma glucose, postprandial glucose, and HbA1c levels in patients with type 2 diabetes mellitus.

Mechanisms of Syzygium cumini

The glucose-lowering effects of Syzygium cumini are associated with its rich content of flavonoids, anthocyanins, tannins, ellagic acid, and glycosides.23 These bioactive constituents may enhance insulin secretion, improve insulin sensitivity, inhibit carbohydrate-digesting enzymes such as α-amylase and α-glucosidase, and reduce oxidative stress. Additionally, Jamun supports glucose utilization and helps regulate postprandial glycemic excursions.24

Clinical Evidence Supporting the Role of Pterocarpus marsupium in Glycemic Control

A randomized single-blind prospective study involving 120 newly diagnosed patients with type 2 diabetes mellitus evaluated the efficacy of Vijaysar (Pterocarpus marsupium), Aloe vera, their combination, and glimepiride over 13 weeks. Patients receiving Vijaysar exhibited a significant reduction in fasting plasma glucose (FPG) from 155.47 mg/dL at baseline to 111.53 mg/dL at the end of treatment, representing a mean decrease of 43.94 mg/dL. Postprandial glucose (2h-PG) levels also declined from 259.10 mg/dL to 178.13 mg/dL, with a mean reduction of 80.97 mg/dL. Additionally, glycemic control targets were achieved in 93% of patients for FPG, 53% for postprandial glucose, and 83% for HbA1c. The study further reported that the effect of Vijaysar on postprandial glucose was comparable to that of glimepiride. These findings suggest that Vijaysar possesses significant antihyperglycemic activity and may improve both fasting and postprandial glycemic control. The observed effects are attributed to its bioactive constituents, particularly pterostilbene and epicatechin, which have been reported to enhance insulin secretion, promote pancreatic β-cell regeneration, inhibit hepatic gluconeogenesis, improve peripheral glucose utilization, and provide antioxidant protection against diabetes-associated oxidative stress. Collectively, these mechanisms support the potential role of Vijaysar as a safe and effective adjunctive therapy in the management of type 2 diabetes mellitus.25

A prospective interventional study involving 52 patients with uncontrolled type 2 diabetes mellitus evaluated the efficacy of Pterocarpus marsupium wood powder (2–4 g/day) as an add-on therapy to conventional oral antidiabetic drugs for 12 weeks. The intervention resulted in a significant reduction in fasting blood glucose from 159.15 ± 30.38 mg/dL to 134.70 ± 30.31 mg/dL, postprandial blood glucose from 240.22 ± 65.77 mg/dL to 198.53 ± 39.66 mg/dL, and HbA1c from 9.39 ± 1.68% to 8.05 ± 1.19% (p < 0.001 for all parameters). The antihyperglycemic activity of P. marsupium is attributed to bioactive compounds such as pterostilbene, marsupin, and epicatechin, which may promote pancreatic β-cell regeneration, enhance insulin secretion, improve insulin sensitivity, reduce intestinal glucose absorption, and provide antioxidant protection against diabetes-associated oxidative stress. These findings suggest that P. marsupium may serve as an effective adjunctive therapy for improving glycemic control in patients with type 2 diabetes mellitus. 26

A single-arm clinical trial involving 40 patients with type 2 diabetes mellitus evaluated the efficacy of Vijaysaradi Ghan Vati administered at a dose of 2 g/day for 28 days. The study demonstrated a significant reduction in fasting blood glucose from 199.28 mg/dL at baseline to 152.78 mg/dL after treatment, representing a mean decrease of 46.5 mg/dL (p < 0.001). Postprandial blood glucose levels also decreased significantly from 315.48 mg/dL to 232.60 mg/dL, corresponding to a mean reduction of 82.88 mg/dL (p < 0.001). In addition to glycemic improvement, patients experienced reductions in classical diabetic symptoms including polyuria, polydipsia, polyphagia, fatigue, burning sensation, and tingling. The antihyperglycemic activity of Vijaysaradi Ghan Vati may be attributed to the synergistic effects of its constituent herbs, including Pterocarpus marsupium, Gymnema sylvestre , Curcuma longa, Berberis aristata, Triphala, Cyperus rotundus, and Momordica charantia. These herbs are reported to enhance insulin sensitivity, support pancreatic β-cell function, inhibit intestinal glucose absorption, improve glucose utilization, and provide antioxidant protection against diabetes-associated oxidative stress. Collectively, these mechanisms contribute to improved glycemic control and metabolic regulation in patients with type 2 diabetes mellitus.27

Clinical Significance

Clinical studies have highlighted the potential of Pterocarpus marsupium as an effective herbal intervention for glycemic control. Supplementation with Vijaysar has been associated with significant reductions in fasting blood glucose, postprandial blood glucose, and HbA1c levels in patients with type 2 diabetes mellitus.

Mechanisms of Pterocarpus marsupium

The antidiabetic effects of Pterocarpus marsupium are attributed to pterostilbene, marsupin, epicatechin, and other polyphenolic compounds.28 These constituents have been reported to support pancreatic β-cell regeneration, stimulate insulin secretion, improve peripheral glucose uptake, enhance insulin sensitivity, and suppress hepatic glucose production. Furthermore, their antioxidant properties help protect pancreatic tissues from oxidative stress associated with chronic hyperglycemia.29,30

Clinical Evidence Supporting the Role of Curcuma longa in Glycemic Control

A randomized, double-blind, placebo-controlled clinical trial involving 70 patients with type 2 diabetes mellitus evaluated the effects of nano-curcumin supplementation (80 mg/day) for 3 months. The intervention significantly reduced fasting blood glucose from 135.5 ± 51.3 mg/dL to 120.3 ± 38.0 mg/dL and HbA1c from 7.59 ± 1.74% to 7.31 ± 1.54% (p < 0.05). Nano-curcumin also improved estimated average glucose (eAG) and body mass index. These antidiabetic effects are attributed to the potent antioxidant and anti-inflammatory properties of curcumin, which may enhance insulin sensitivity, inhibit NF-κB-mediated inflammation, activate PPAR-γ signaling, and reduce oxidative stress associated with insulin resistance. The nano-formulation provides superior bioavailability compared with conventional curcumin, thereby enhancing its therapeutic efficacy in glycemic control.31

A randomized double-blind, placebo-controlled clinical trial evaluated the efficacy of Curcuma longa L. (500 mg/day) supplemented with piperine (5 mg/day) in 61 patients with type 2 diabetes mellitus over a period of 120 days. Participants receiving the intervention demonstrated significant improvements in several metabolic parameters compared with the placebo group. Fasting venous glucose (FVG) decreased from 203.9 mg/dL to 197.3 mg/dL, glycated hemoglobin (HbA1c) declined from 8.6% to 8.5%, and the HOMA-IR index showed a significant reduction, indicating improved insulin sensitivity. A marked reduction in triglyceride levels was also observed, decreasing from 235.3 mg/dL to 186.2 mg/dL, representing an approximately 21% reduction. Furthermore, significant decreases in LDL-cholesterol, systolic blood pressure, and diastolic blood pressure were reported in the intervention group. The beneficial effects of Curcuma longa are attributed to curcumin, its principal bioactive constituent, which enhances glucose homeostasis by stimulating glycolysis, suppressing gluconeogenesis, improving insulin sensitivity, reducing insulin resistance, and supporting pancreatic β-cell function. Piperine was incorporated to increase curcumin bioavailability, which has been reported to enhance curcumin absorption by more than 2000%. The study concluded that daily supplementation with Curcuma longa and piperine significantly improved glycemic control and lipid metabolism in patients with type 2 diabetes, suggesting its potential role as an adjunctive dietary intervention for metabolic management.32

Clinical Significance

Clinical research indicates that Curcuma longa possesses beneficial effects in the metabolic management of type 2 diabetes mellitus. Supplementation with curcumin has been shown to improve glycemic control, reduce HbA1c levels, enhance insulin sensitivity, and improve lipid metabolism. In addition, curcumin may help reduce cardiovascular risk factors associated with diabetes by lowering triglyceride levels, improving endothelial function, and decreasing oxidative stress.

Mechanisms of Curcuma longa

Curcumin, the principal bioactive constituent of Curcuma longa, exerts multiple beneficial effects on glucose metabolism.33 It improves insulin sensitivity, suppresses inflammatory pathways such as NF-κB signaling, reduces oxidative stress, enhances glucose uptake, and supports pancreatic β-cell function.34,35 Curcumin may also improve lipid metabolism and endothelial function, thereby reducing cardiovascular risk factors commonly associated with diabetes.

Conlusion

DiaboFood® combines scientifically supported botanical extracts and nutritional ingredients that target multiple pathways involved in type 2 diabetes mellitus. Its ingredients help improve insulin sensitivity, support pancreatic β-cell function, reduce intestinal glucose absorption, suppress oxidative stress and inflammation, promote healthy gut microbiota, and enhance glucose metabolism. Together, these complementary mechanisms contribute to healthy fasting blood glucose levels, glycemic balance, and overall metabolic health.

Reference:

1. Diabetes Facts and Figures show global impact for individuals, families and countries [Internet]. [cited 2026 Jun 18]. Available from: https://idf.org/about-diabetes/diabetes-facts-figures/
2. Madhu SV. Defying the Odds: Conquering Prediabetes for a Diabetes-Free Tomorrow. Indian J Endocrinol Metab. 2023;27(4):273–6. doi:10.4103/2230-8210.388224 PubMed PMID: 37867977; PubMed Central PMCID: PMC10586560.
   
3. Mohan V. Why are Indians more prone to diabetes? J Assoc Physicians India. 2004 Jun;52:468–74. PubMed PMID: 15645957.
   
4. Hossain MdJ, Al‐Mamun Md, Islam MdR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Sci Rep. 2024 Mar 22;7(3):e2004. doi:10.1002/hsr2.2004 PubMed PMID: 38524769; PubMed Central PMCID: PMC10958528.
   
5. Abela AG, Fava S. Why is the Incidence of Type 1 Diabetes Increasing? Curr Diabetes Rev. 2021;17(8):e030521193110. doi:10.2174/1573399817666210503133747 PubMed PMID: 33949935.
   
6. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020 Aug 30;21(17):6275. doi:10.3390/ijms21176275 PubMed PMID: 32872570; PubMed Central PMCID: PMC7503727.
   
7. Vybhavi VSJ, Bhavsar M, Gusani J, Gohil Y, Paul NK, Garlapati HR, et al. New Insights into the Pathophysiology of Type 2 Diabetes: A Review Article. J Pharm Bioallied Sci. 2025 Jun;17(Suppl 2):S1070–2. doi:10.4103/jpbs.jpbs_1759_24 PubMed PMID: 40655865; PubMed Central PMCID: PMC12244730.
   
8. Sanches JM, Zhao LN, Salehi A, Wollheim CB, Kaldis P. Pathophysiology of type 2 diabetes and the impact of altered metabolic interorgan crosstalk. FEBS J. 2023 Feb;290(3):620–48. doi:10.1111/febs.16306 PubMed PMID: 34847289.
   
9. Lu X, Xie Q, Pan X, Zhang R, Zhang X, Peng G, et al. Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Signal Transduct Target Ther. 2024 Oct 2;9(1):262. doi:10.1038/s41392-024-01951-9 PubMed PMID: 39353925; PubMed Central PMCID: PMC11445387.
   
10. Sadagopan A, Mahmoud A, Begg M, Tarhuni M, Fotso M, Gonzalez NA, et al. Understanding the Role of the Gut Microbiome in Diabetes and Therapeutics Targeting Leaky Gut: A Systematic Review. Cureus. 15(7):e41559. doi:10.7759/cureus.41559 PubMed PMID: 37554593; PubMed Central PMCID: PMC10405753.
    
11. Modak M, Dixit P, Londhe J, Ghaskadbi S, Paul A. Devasagayam T. Indian Herbs and Herbal Drugs Used for the Treatment of Diabetes. J Clin Biochem Nutr. 2007 May;40(3):163–73. doi:10.3164/jcbn.40.163 PubMed PMID: 18398493; PubMed Central PMCID: PMC2275761.
    
12. Cheng M, Ding F, Li L, Dai C, Sun X, Xu J, et al. Exploring the role of curcumin in mitigating oxidative stress to alleviate lipid metabolism disorders. Front Pharmacol. 2025 Jan 30;16:1517174. doi:10.3389/fphar.2025.1517174 PubMed PMID: 39950117; PubMed Central PMCID: PMC11822302.
    
13. Rao TP, Sakaguchi N, Juneja LR, Wada E, Yokozawa T. Amla (Emblica officinalis Gaertn.) extracts reduce oxidative stress in streptozotocin-induced diabetic rats. J Med Food. 2005;8(3):362–8. doi:10.1089/jmf.2005.8.362 PubMed PMID: 16176148.
    
14. Mahalak KK, Firrman J, Narrowe AB, Hu W, Jones SM, Bittinger K, et al. Fructooligosaccharides (FOS) differentially modifies the in vitro gut microbiota in an age-dependent manner. Front Nutr. 2023 Jan 12;9:1058910. doi:10.3389/fnut.2022.1058910 PubMed PMID: 36712525; PubMed Central PMCID: PMC9879625.
    
15. Office of Dietary Supplements - Vitamin B12 [Internet]. [cited 2026 Jun 20]. Available from: https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/
    
16. Vyas P, Binawara BK, Narnolia PK. Effect of Gurmar (Gymnema sylvestre) Leaf Powder on Glycemic Control in Type 2 Diabetes Mellitus.
    
17. Kumar SN, Mani UV, Mani I. An open label study on the supplementation of Gymnema sylvestre in type 2 diabetics. J Diet Suppl. 2010 Sep;7(3):273–82. doi:10.3109/19390211.2010.505901 PubMed PMID: 22432517.
    
18. Nema NK, Sarojam S, K K, Devanpally C, Jacob V. Assessment of Gymnema sylvestre in association with magnesium and vitamin D3 on glycemic control in type 2 diabetes mellitus: A prospective, open-label, single-arm study with possible mechanistic insights. Clinical Traditional Medicine and Pharmacology. 2026 Jun 1;7(2):200286. doi:10.1016/j.ctmp.2026.200286
    
19. Chauhan S, Kumbar PA. Antidiabetic activity of Herbomineral formulation (GASY) in the management of Prameha with special reference to Type 2 Diabetes Mellitus- An experimental and pilot clinical study. Annals of Ayurvedic Medicine. 2025 Oct 5;14(3):325–325. doi:10.5455/AAM.202361
    
20. Tiwari P, Mishra BN, Sangwan NS. Phytochemical and Pharmacological Properties of Gymnema sylvestre: An Important Medicinal Plant. Biomed Res Int. 2014;2014:830285. doi:10.1155/2014/830285 PubMed PMID: 24511547; PubMed Central PMCID: PMC3912882.
    
21. Department of Medicine Rukmani Devi Beni Prasad Jaipuriya Hospital, Jaipur, Sanwalka DN. Study of effect of jamun (Syzygium cumini) seed powder on glycemic control and dyslipidemia in type 2 diabetes mellitus a double blind randomized control trial. jmscr. 2019 Sep 19;7(9). doi:10.18535/jmscr/v7i9.71
    
22. Sidana S, Singh VB, Meena BL, Beniwal S, Singh K, Kumar D, et al. Effect of Syzygium cumini (jamun) seed powder on glycemic control: A double-blind randomized controlled trial. Journal of Medical Society. 2017 Dec;31(3):185. doi:10.4103/jms.jms_62_16
    
23. Adithya BS, Nayeem M, Sagar NA, Kumar S. Therapeutic Potentials of Jamun (Syzygium cumini) and Its Integration Into Modern Food Technologies: A Review. Int J Food Sci. 2025 Aug 10;2025:8197889. doi:10.1155/ijfo/8197889 PubMed PMID: 40831544; PubMed Central PMCID: PMC12358234.
    
24. Franco RR, Ribeiro Zabisky LF, Pires de Lima Júnior J, Mota Alves VH, Justino AB, Saraiva AL, et al. Antidiabetic effects of Syzygium cumini leaves: A non-hemolytic plant with potential against process of oxidation, glycation, inflammation and digestive enzymes catalysis. Journal of Ethnopharmacology. 2020 Oct 28;261:113132. doi:10.1016/j.jep.2020.113132
    
25. Maurya AK, Jain A, Pathak A, Chaudhary P, Rajdan N. Efficacy of vijaysar, aloevera alone and their combination in the treatment of newly diagnosed cases of type 2 diabetes mellitus: a randomized single blind prospective study. International Journal of Basic & Clinical Pharmacology. 2017 Mar 25;6(4):962–7. doi:10.18203/2319-2003.ijbcp20171112
    
26. Patidar A, Tonpay SD, Agrawal N. Hypoglycemic activity of Pterocarpus marsupium in patients with Type 2 diabetes mellitus. International Journal of Basic & Clinical Pharmacology. 2015;4(6):1189–93. doi:10.18203/2319-2003.ijbcp20151356
    
27. Dipankar D, Dubal N. Integrated Ayurvedic Management of Prameha with Special Reference to Type 2 Diabetes Mellitus: A Comprehensive Clinical Investigation [SSRN Scholarly Paper] [Internet]. Rochester, NY: Social Science Research Network; 2025 [cited 2026 Jun 18]. Available from: https://papers.ssrn.com/abstract=5092352 doi:10.2139/ssrn.5092352
    
28. Pterocarpus marsupium - an overview | ScienceDirect Topics [Internet]. [cited 2026 Jun 20]. Available from: https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/pterocarpus-marsupium
    
29. Rizvi SI, Mishra N. Traditional Indian Medicines Used for the Management of Diabetes Mellitus. J Diabetes Res. 2013;2013:712092. doi:10.1155/2013/712092 PubMed PMID: 23841105; PubMed Central PMCID: PMC3687502.
    
30. Mekala S, Mchenga SSS, R S. Antidiabetic effect of Pterocarpus marsupium seed extract in gabapentin induced diabetic rats. International Journal of Basic & Clinical Pharmacology. 2020 Feb 25;9(3):371–7. doi:10.18203/2319-2003.ijbcp20200707
    
31. Rahimi HR, Mohammadpour AH, Dastani M, Jaafari MR, Abnous K, Ghayour Mobarhan M, et al. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna J Phytomed. 2016;6(5):567–77. PubMed PMID: 27761427; PubMed Central PMCID: PMC5052420.
    
32. Neta JF de F, Veras VS, Sousa DF de, Cunha M da C dos SO, Queiroz MVO, Neto JCGL, et al. Effectiveness of the piperine-supplemented Curcuma longa L. in metabolic control of patients with type 2 diabetes: a randomised double-blind placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition. 2021 Oct 3;72(7):968–77. doi:10.1080/09637486.2021.1885015 PubMed PMID: 33586583.
    
33. Pathomwichaiwat T, Jinatongthai P, Prommasut N, Ampornwong K, Rattanavipanon W, Nathisuwan S, et al. Effects of turmeric (Curcuma longa) supplementation on glucose metabolism in diabetes mellitus and metabolic syndrome: An umbrella review and updated meta-analysis. PLoS One. 2023 Jul 20;18(7):e0288997. doi:10.1371/journal.pone.0288997 PubMed PMID: 37471428; PubMed Central PMCID: PMC10359013.
    
34. NF‐κB pathway as a molecular target for curcumin in diabetes mellitus treatment: Focusing on oxidative stress and inflammation - Zamanian - 2024 - Cell Biochemistry and Function - Wiley Online Library [Internet]. [cited 2026 Jun 20]. Available from: https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/cbf.4030
    
35. Roney M, Mohd Aluwi MFF. Unraveling the Systems Biology of Curcumin: A Mini-review of its Anti-diabetic Potential through Network Pharmacology. Cell Biochem Biophys. 2026;84(1):107–29. doi:10.1007/s12013-025-01888-y PubMed PMID: 40928585; PubMed Central PMCID: PMC12967660.